| The pharmacological treatment of primary aldosteronism. | |
| | |
MedLine Citation:
|
PMID: 16553572 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Aldosterone is increasingly considered to have a fundamental role in the pathophysiology of cardiovascular disease. Primary aldosteronism is a much more common cause of secondary hypertension than once suspected, accounting for approximately 10% of cases. Screening for primary aldosteronism should be considered even in the presence of normokalaemia. The non-classical effects of aldosterone, some of which are transcription-independent, may be of similar or greater importance than its traditional effects on the kidney. Treatment of primary aldosteronism should be specific and aim to ameliorate all hormone-related effects of aldosterone, not just the most obvious manifestation of hypertension. Mineralocorticoid antagonism, shown to lead to significant additional survival advantage in heart failure, offers the best prospect for achieving therapeutic goals. For the increasing proportion of patients with primary aldosteronism suitable for long-term medical treatment, mineralocorticoid receptor blockade (better tolerated with eplerenone) should be considered the most appropriate choice of treatment, pending the development of better alternatives. |
| | |
Authors:
|
Salim Janmohamed; Pierre-Marc G Bouloux |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 7 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2006 Apr |
Date Detail:
|
Created Date: 2006-03-23 Completed Date: 2006-08-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 563-73 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, Royal Free Hospital, London, NW3 2QG, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
metabolism Aldosterone Antagonists / pharmacology, therapeutic use Amiloride / pharmacology, therapeutic use Calcium Channel Blockers / pharmacology, therapeutic use Clinical Trials as Topic Drug Therapy, Combination Glucocorticoids / pharmacology, therapeutic use Humans Hyperaldosteronism / complications, drug therapy*, metabolism Hypertension / etiology, prevention & control Practice Guidelines as Topic Receptors, Aldosterone / antagonists & inhibitors, metabolism Sodium Channel Blockers / pharmacology, therapeutic use Spironolactone / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Calcium Channel Blockers; 0/Glucocorticoids; 0/Receptors, Aldosterone; 0/Sodium Channel Blockers; 2609-46-3/Amiloride; 52-01-7/Spironolactone; 52-39-1/Aldosterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The management of behavioural and psychiatric symptoms in delirium.
Next Document: The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical t...